Appareil pulmonaire IONESCO (IFCT-1601) A Phase II Prospective Immune Neoadjuvant Therapy Study of Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer. Saint-Cloud MARIE ANGE MASSIANI
Appareil pulmonaire AK112-301-HARMONi A randomized, double-blind, multi-center, Phase III Study of AK112 or placebo combined with;pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic nonsquamous;NSCLC who have failed to EGFR-TKI treatment. Paris NICOLAS GIRARD
Appareil pulmonaire AMGEN_20210004 (AMG 757) A Randomized, Open-label, Phase 3 Study of;Tarlatamab Compared With Standard of Care in;Subjects With Relapsed Small Cell Lung Cancer;After Platinum-based First-line Chemotherapy;(DeLLphi-304) Paris NICOLAS GIRARD
Appareil pulmonaire CodeBreak202 A Phase 3, Multicenter, Randomized, Open-label;Study Evaluating Efficacy of Sotorasib Platinum;Doublet Combination Versus Pembrolizumab;Platinum Doublet Combination as a Front-Line;Therapy in Subjects With Stage IV or Advanced;Stage IIIB/C Nonsquamous NonÀSmall Cell Lung;Cancers, Negative for PD-L1, and Positive for;KRAS p.G12C (CodeBreaK 202) Paris NICOLAS GIRARD
Sein métastatique RH+ CT7001_003 (SUMIT ELA) A Phase 1b/2 Open-label Study of Samuraciclib in Combination with Elacestrant in;Participants with Metastatic or Locally Advanced Hormone Receptor-positive and Human;Epidermal Growth Factor Receptor 2-negative Breast Cancer. Saint-Cloud FRANCOIS-CLEMENT BIDARD
Appareil pulmonaire DS 73001-003 A PHASE 2, MULTICENTER, RANDOMIZED, OPENLABEL;STUDY OF DS-7300A, A B7-H3 ANTIBODY;DRUG CONJUGATE (ADC), IN SUBJECTS WITH;PRETREATED EXTENSIVE-STAGE SMALL CELL;LUNG CANCER (ES-SCLC). Paris PAULINE DU RUSQUEC
Appareil pulmonaire TAS6417-201 An Open-Label, Phase 2b, Global Multicenter Cohort Trial to;Assess the Safety and Efficacy of Zipalertinib in Patients;with Locally Advanced or Metastatic Non-Small Cell Lung;Cancer with Exon 20 Insertion and Uncommon/Single or;Compound Epidermal Growth Factor Receptor Mutations. Paris NICOLAS GIRARD
Sein métastatique RH+ AIPAC AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel Saint-Cloud ETIENNE BRAIN
Sein métastatique RH+ BYLieve (CBYL719X402) A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment Saint-Cloud FLORENCE LEREBOURS
Gynécologie - Ovaires FORWARD-1 FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Saint-Cloud ANNE DONNADIEU